Novel Strategies For Improving Syphilis Testing And Control
Funder
National Health and Medical Research Council
Funding Amount
$1,256,041.00
Summary
Syphilis has been resurgent in many countries including Australia. Our research will evaluate novel strategies to improve syphilis testing, surveillance, and control and ensure these new strategies are effective at targeting affected groups attending health services. The research findings will help guide better syphilis testing and control by health care providers, pathology services and health policy makers.
Using Mathematical Models To Assess The Impact Of Interventions To Reduce Sexually Transmitted Infections In Australia
Funder
National Health and Medical Research Council
Funding Amount
$562,276.00
Summary
Sexually transmitted infections (STIs) are an increasing public health problem in Australia. Australia's recent National Transmissible Infections Strategy identified chlamydia control, STI prevention in gay men and STIs in Aboriginal and Torres Strait Islander communities as priority areas. We propose to develop mathematical models of STI transmission and use these to help understand and identify the most cost-effective interventions to reduce the impact of STIs on Australian populations.
The Indigenous Australian Malnutrition project aims to explore the burden and impact of malnutrition particularly for Aboriginal and Torres Strait Islander patients in hospital. The project includes the development and validation of the Australian Nutrition Tool (ANT) and validating the Malnutrition Screening Tool (MST) as an appropriate screening tool for Indigenous Australian patients. The project also aims to determine the prevalence of adult malnutrition and explore its burden and impact.
Whole-of-population CRISPR Point-of-care Testing For Congenital Cytomegalovirus To Prevent Hearing And Neurodevelopment Disabilities Through A Public Health Approach
Funder
National Health and Medical Research Council
Funding Amount
$2,058,920.00
Summary
Congenital cytomegalovirus infection (cCMV) is the major infective cause of deafness and brain disability, both of which are potentially reversible with early treatment. Currently, there is no screening at birth, and cCMV is diagnosed too late for treatment. Our team will test and validate CRISPR, a new and cheap technology, on 110,000+ newborns to detect cCMV. This will revolutionise how cCMV is detected, make treatment more accessible and pave way to lower rates of deafness and cerebral palsy.